Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports
Authors:
Open Access
- 14 October 2021
- journal article
- letter
- Published by Wiley in Clinical and Translational Allergy
- Vol. 11 (8) , e12067
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline (Study, 204710)
This publication has 5 references indexed in Scilit:
- Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real lifeWorld Allergy Organization Journal, 2021
- Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysisEuropean Respiratory Journal, 2020
- Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programmeEuropean Respiratory Journal, 2020
- The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness GroupEuropean Respiratory Journal, 2019
- Randomised controlled trials in severe asthma: selection by phenotype or stereotypeEuropean Respiratory Journal, 2018